Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McNeil Single-Active Children’s Cough/Cold OTCs Stress Simplicity, Safety

This article was originally published in The Tan Sheet

Executive Summary

Simply Stuffy and Simply Cough cold medicines - "from the makers of Children's Tylenol" - are designed to reduce consumer confusion and alleviate pediatricians' concerns about unnecessarily medicating children, McNeil Consumer & Specialty Pharmaceuticals maintained

You may also be interested in...



Acetaminophen Pediatric Concentrations Standardization Urged By NDAC

A pending proposed rule on pediatric acetaminophen dosing reflects concerns voiced by FDA's Nonprescription Drugs Advisory Committee about the need for standardizing pediatric formula concentrations, Division of OTC Drug Products Director Charles Ganley, MD, told the committee Sept. 19

Voluntary Acetaminophen Labeling Revisions Include Overdose Warning

McNeil Consumer & Specialty Pharmaceuticals and Bayer Consumer Care are revising acetaminophen product labeling to add a distinct "overdose warning," the companies say in materials submitted to FDA's Nonprescription Drugs Advisory Committee

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel